ResMed News

A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $280 to $280

Moomoo NewsOct 2 09:03 ET

Bank of America Securities Sticks to Its Buy Rating for Resmed (RMD)

TipRanksOct 1 10:00 ET

Needham Maintains ResMed(RMD.US) With Hold Rating

Moomoo NewsOct 1 06:31 ET

Needham Reaffirms Their Hold Rating on Resmed (RMD)

TipRanksOct 1 05:50 ET

ResMed Analyst Ratings

BenzingaOct 1 05:32 ET

Mizuho Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $250

Moomoo NewsSep 30 12:32 ET

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)

TipRanksSep 27 13:32 ET

Baird Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $280

Moomoo NewsSep 27 13:32 ET

BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $270

Moomoo NewsSep 26 05:33 ET

Resmed Poised for Growth Amid Rising OSA Diagnosis and Market Opportunity: Buy Rating Reaffirmed With Increased Price Objective

TipRanksSep 26 05:18 ET

ResMed Analyst Ratings

BenzingaSep 24 06:27 ET

Baird Initiates ResMed(RMD.US) With Buy Rating, Announces Target Price $280

Moomoo NewsSep 23 16:31 ET

Needham Maintains ResMed(RMD.US) With Hold Rating

Moomoo NewsSep 18 06:31 ET

Resmed (RMD) Receives a Hold From Needham

TipRanksSep 18 06:19 ET

ResMed Analyst Ratings

BenzingaSep 18 05:52 ET

Wolfe Research Downgrades ResMed(RMD.US) to Sell Rating, Announces Target Price $180

Moomoo NewsSep 18 05:31 ET

Wolfe Research Downgrades ResMed to Underperform From Peer Perform, Price Target Is $180

MT NewswiresSep 18 05:19 ET

ResMed Faces Market Disruption and Limited Growth: A Sell Rating Analysis

TipRanksSep 18 04:53 ET

Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)

TipRanksSep 11 05:04 ET

ResMed Price Target Maintained With a $236.00/Share by Needham

Dow JonesSep 4 06:09 ET